Company intelligence / Profile preview
Maxwell Biosciences
- Ownership
- Private
- Development stage
- Other
Overview
Maxwell’s CLAROMER® compounds have demonstrated broad-spectrum efficacy against a wide range of viruses (including all tested Influenza and Coronaviruses), bacteria—including antibiotic-resistant strains—fungi and biofilms in preclinical animal models. The compounds act via selective membrane disruption of pathogens while sparing healthy cells. They are well tolerated at high doses in animal studies and human tissues ex vivo. A nasal spray candidate has completed successful animal studies sponsored by NIAID with positive FDA feedback; an oral formulation for GI infections is also under development.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Synthetic small molecules (peptidomimetics)Biomimetic therapeutics inspired by antimicrobial peptides (e.g., LL-37)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Maxwell Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maxwell Biosciences.